What they were paid
CRISPR Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | — | $0 | — | — | — |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRISPR Therapeutics AG DEF 14A filed April 21, 2026, accession 0001193125-26-165158, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025CRISPR Therapeutics pays directors a $50,000 cash retainer and $285,740 in Options.
Committees
FY2025 · as the proxy prints themAudit
The rest of the CRISPR Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Ali Behbahani | Independent Director | $348,240 |
| Briggs W. Morrison | Independent Director | $341,069 |
| Christian Rommel | Independent Director | $335,740 |
| Douglas A. Treco | Independent Director | $370,740 |
| H. Edward Fleming Jr | Independent Director | $343,354 |
| John T. Greene | Independent Director | $363,917 |
| Katherine A. High | Independent Director | $358,123 |
| Maria Fardis | Independent Director | $349,715 |
| Samarth Kulkarni | Chair of the Board | $0 |
| Simeon J. George | Independent Director | $342,168 |
The full CRISPR Therapeutics compensation record
free company briefThis page is one director within CRISPR Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat